An interventional study of Blinatumomab in B Cell Precursor Acute Lymphoblastic Leukemia, Pediatric and Minimal Residual Disease, sponsored by The Children's Hospital of Zhejiang University School of Medicine. Not yet recruiting. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2025-01-08.
Sponsored by The Children's Hospital of Zhejiang University School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing blinatumomab in Neoplasm, Residual — 3 open to participants now, 6 under way, none of them phase 3. blinatumomab · Neoplasm, Residual.
Among the 17 studies testing blinatumomab in Neoplasm, Residual, this one has the largest planned enrollment, is one of 3 that started in 2025, is one of 2 with no phase, and was the 15th registered.
294 studies on the registry are indexed under Neoplasm, Residual; 137 are open to participants now.
Browse Neoplasm, Residual studies →3 of the 17 studies testing blinatumomab in Neoplasm, Residual are open now, in 1 country. Recruiting first, the newest first:
First Affiliated Hospital of Zhejiang University · Sites in China
Ages 18–65
Zhejiang University · Sites in China
Ages 18–70
By country, each count listing its studies:
blinatumomab: first FDA approval 2014 (BLINCYTO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 93 Neoplasm, Residual studies recruiting now, 59 (63%) set no upper age limit and 24 (26%) stop at 75 or younger; 18 take children under 18; 7 take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 1,220 is above the median of 50 across 199 interventional studies indexed under Neoplasm, Residual.
Median enrollment 31 across the 17 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 17 have an industry lead sponsor. The 10 most frequent:
The Children's Hospital of Zhejiang University School of Medicine is the lead sponsor of 69 studies on the registry; 52 are open to participants now.
The Children's Hospital of Zhejiang University School of Medicine has 1 study filed under Neoplasm, Residual — fewer than ten, so there is no comparison to draw.
2 of the studies testing blinatumomab in Neoplasm, Residual that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003737First Affiliated Hospital of Zhejiang UniversityBlinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation | 2027-02-05 |
| NCT04521231AmgenA Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | 2027-11-24 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing blinatumomab in Neoplasm, Residual, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment.
The main questions it aims to answer are:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC). If NGS MRD is positive (≥0.0001%), one course of blinatumomab (28 days) will be added after the consolidation treatment.
Drug: Blinatumomab
Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC). If NGS MRD is negative (\< 0.0001%), the IR/HR patients will be randomized into A and B two groups. EOC NGS MRD negative Group A will be added by one course of blinatumomab (28 days) treatment after the consolidation treatment.
Drug: Blinatumomab
Based on the B-ALL treatment protocol, NGS MRD levels will be monitored at the end of consolidation treatment (EOC). If NGS MRD is negative (\< 0.0001%), the IR/HR patients will be randomized into A and B two groups. EOC NGS MRD negative Group B will continue the original chemotherapy treatment plan.
The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.
event free survival
Death during induction, abandonment before complete remission, death in continuous complete remission, relapse, and secondary Death during induction, abandonment before complete remission (CR), death in continuous complete remission (CCR), relapse, and secondary malignancies were considered as events in the calculation of EFS probability.
Time frame: From enrollment to the 3-year after the end of treatment
Relapse free survival
RFS was measured by the time from achievement of CR to last follow-up or first relapse and censored at the first event (death, secondary malignancies) except relapse.
Time frame: From enrollment to the 3-year after the end of treatment
Treatment-Related Adverse Events as Assessed by CTCAE v4.0
Time frame: From enrollment to the 3-year after the end of treatment
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jan 2025; primary completion for Dec 2027, 35 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Blinatumomab
The Children's Hospital of Zhejiang University School of Medicine